USD
0.00
(0.00%
)AT CLOSE (AS OF Aug 14, 2025)
$32B
MARKET CAP
27.41
P/E Ratio
6.91
EPS
$253
52 Week High
$135
52 Week Low
TRADE & SERVICES
Sector
Automate your trading workflow with powerful tools — built for serious traders.
Field | Value (USD) |
---|---|
Gross Profit | $5.4B |
Total Revenue | $15B |
Cost Of Revenue | $10B |
Costof Goods And Services Sold | $10B |
Operating Income | $2.2B |
Selling General And Administrative | $2B |
Research And Development | - |
Operating Expenses | $3.2B |
Investment Income Net | - |
Net Interest Income | -$623M |
Interest Income | $47M |
Interest Expense | $670M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $1.1B |
Income Before Tax | $1.7B |
Income Tax Expense | $301M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $1.4B |
Comprehensive Income Net Of Tax | - |
Ebit | $2.4B |
Ebitda | $3.5B |
Net Income | $1.4B |
Field | Value (USD) |
---|---|
Total Assets | $27B |
Total Current Assets | $5.8B |
Cash And Cash Equivalents At Carrying Value | $1.7B |
Cash And Short Term Investments | $1.7B |
Inventory | - |
Current Net Receivables | $3.2B |
Total Non Current Assets | $21B |
Property Plant Equipment | $773M |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $4.5B |
Intangible Assets Excluding Goodwill | $4.5B |
Goodwill | $15B |
Investments | - |
Long Term Investments | $374M |
Short Term Investments | $141M |
Other Current Assets | $746M |
Other Non Current Assets | - |
Total Liabilities | $21B |
Total Current Liabilities | $7B |
Current Accounts Payable | $736M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $1.1B |
Total Non Current Liabilities | $14B |
Capital Lease Obligations | $173M |
Long Term Debt | $13B |
Current Long Term Debt | $1.1B |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $14B |
Other Current Liabilities | $3.1B |
Other Non Current Liabilities | $668M |
Total Shareholder Equity | $6.1B |
Treasury Stock | - |
Retained Earnings | $6.1B |
Common Stock | $3M |
Common Stock Shares Outstanding | $183M |
Field | Value (USD) |
---|---|
Operating Cashflow | $2.7B |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $1.1B |
Capital Expenditures | $602M |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$1.4B |
Cashflow From Financing | -$878M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$1.4B |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $1.4B |
Field | Value (USD) |
---|---|
Gross Profit | $5.4B |
Total Revenue | $15B |
Cost Of Revenue | $10B |
Costof Goods And Services Sold | $10B |
Operating Income | $2.2B |
Selling General And Administrative | $2B |
Research And Development | - |
Operating Expenses | $3.2B |
Investment Income Net | - |
Net Interest Income | -$623M |
Interest Income | $47M |
Interest Expense | $670M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $1.1B |
Income Before Tax | $1.7B |
Income Tax Expense | $301M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $1.4B |
Comprehensive Income Net Of Tax | - |
Ebit | $2.4B |
Ebitda | $3.5B |
Net Income | $1.4B |
Sector: TRADE & SERVICES
Industry: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.